Compare SFIX & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFIX | CERS |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.3M | 465.5M |
| IPO Year | 2017 | 1996 |
| Metric | SFIX | CERS |
|---|---|---|
| Price | $2.56 | $2.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.40 | ★ $5.13 |
| AVG Volume (30 Days) | ★ 3.6M | 1.7M |
| Earning Date | 12-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.09 | 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,226,505,000.00 | $51,326,000.00 |
| Revenue This Year | N/A | $20.82 |
| Revenue Next Year | $3.40 | $9.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 25.52 | ★ 30.68 |
| 52 Week Low | $2.10 | $1.38 |
| 52 Week High | $5.75 | $3.47 |
| Indicator | SFIX | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 47.16 |
| Support Level | $2.28 | $2.20 |
| Resistance Level | $2.88 | $3.12 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 47.50 | 74.58 |
Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.